Aurora Cannabis (ACB) Cash from Restructuring (2018 - 2022)

Aurora Cannabis (ACB) posted quarterly Cash from Restructuring of $2.1 million for Q2 2022, up 753.76% on a QoQ basis from -$327647.8 in Q4 2021.

Aurora Cannabis (ACB) Cash from Restructuring (2018 - 2022) Analysis & Trends

Aurora Cannabis (ACB) has reported Cash from Restructuring for 4 consecutive years, with $2.1 million the latest figure, recorded in Q2 2022.

  • Quarterly Cash from Restructuring changed N/A year-over-year to $2.1 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $2.5 million (changed N/A YoY) and the FY2022 annual result came in at $2.2 million, changed N/A from the prior year.
  • Cash from Restructuring climbed to $2.1 million in Q2 2022 per ACB's latest filing, from -$327647.8 in the prior quarter.
  • Over the last five years, Cash from Restructuring for ACB reached as high as $2.1 million in Q2 2022 and fell as low as -$327647.8 in Q4 2021.
  • A 4-year average of $1.1 million and a median of $1.5 million in 2019 frame the typical range for Cash from Restructuring.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Aurora Cannabis 1.11 Bn 1.03 Bn 21.72 Mn

Historic Data

Download Data
DateValue
Jun 30, 2022 2.14 Mn
Dec 31, 2021 -327,647.80
Sep 30, 2021 645,854.77
Mar 31, 2019 1.51 Mn
Sep 30, 2018 1.71 Mn